Articles

Search Articles

Advanced search
Help

Catalogue

Articles

Databases

X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
clinical neurology (5) 5
female (5) 5
humans (5) 5
male (5) 5
aged (4) 4
middle aged (4) 4
myasthenia gravis (4) 4
activities of daily living (3) 3
adult (3) 3
amyotrophic lateral sclerosis (3) 3
amyotrophic lateral sclerosis - genetics (3) 3
amyotrophic-lateral-sclerosis (3) 3
index medicus (3) 3
prognosis (3) 3
acetylcholine-receptor (2) 2
amyotrophic lateral sclerosis - mortality (2) 2
complement inhibitor eculizumab (2) 2
disease progression (2) 2
eculizumab (2) 2
medicine & public health (2) 2
mutation (2) 2
myasthenia (2) 2
neuromuscular junctions (2) 2
neurosciences (2) 2
patients (2) 2
progression (2) 2
public health (2) 2
quality of life (2) 2
quality of life research (2) 2
severity of illness index (2) 2
sociology, general (2) 2
superoxide dismutase - genetics (2) 2
survival (2) 2
abridged index medicus (1) 1
activation (1) 1
adolescent (1) 1
adult; aged; antibodies, monoclonal, humanized; autoantibodies; double-blind method; drug resistance; female; humans; male; middle aged; myasthenia gravis; receptors, cholinergic; outcome assessment; severity of illness index; neurology (1) 1
age factors (1) 1
aged, 80 and over (1) 1
algorithm (1) 1
als (1) 1
amyotrophic lateral sclerosis - cerebrospinal fluid (1) 1
amyotrophic lateral sclerosis - diagnosis (1) 1
amyotrophic lateral sclerosis - drug therapy (1) 1
amyotrophic lateral sclerosis - epidemiology (1) 1
amyotrophic lateral sclerosis - immunology (1) 1
amyotrophic lateral sclerosis - pathology (1) 1
amyotrophic lateral sclerosis - physiopathology (1) 1
analysis (1) 1
animal-model (1) 1
animals (1) 1
anti-bacterial agents - pharmacology (1) 1
anti-bacterial agents - therapeutic use (1) 1
antibodies (1) 1
antibodies, monoclonal, humanized - administration & dosage (1) 1
antibodies, monoclonal, humanized - adverse effects (1) 1
antibodies, monoclonal, humanized - pharmacology (1) 1
antibody (1) 1
autoantibodies - blood (1) 1
awaji (1) 1
belgium - epidemiology (1) 1
biochemistry & molecular biology (1) 1
biomarkers - cerebrospinal fluid (1) 1
brief communication (1) 1
c3 (1) 1
c9 (1) 1
case-control studies (1) 1
cell survival - drug effects (1) 1
cell survival - physiology (1) 1
child (1) 1
clinical (1) 1
clinical characteristics (1) 1
clinical research article (1) 1
clinical research articles (1) 1
clinical s (1) 1
complement (1) 1
correction (1) 1
criteria (1) 1
cross-sectional studies (1) 1
csf (1) 1
cu/zn superoxide dismutase (1) 1
cu/zn superoxide-dismutase (1) 1
daily living profile (1) 1
delayed diagnosis - trends (1) 1
diagnosis (1) 1
diagnosis, differential (1) 1
disease models, animal (1) 1
dose-response relationship, drug (1) 1
double-blind (1) 1
double-blind method (1) 1
drug resistance (1) 1
effectiveness (1) 1
el-escorial (1) 1
electrodiagnosis - standards (1) 1
electrodiagnosis - trends (1) 1
electrodiagnostic testing (1) 1
electromyography (1) 1
electromyography - standards (1) 1
electromyography - trends (1) 1
end-plate (1) 1
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


1. Full Text Neurofilament markers for ALS correlate with extent of upper and lower motor neuron disease
by Poesen, Koen and De Schaepdryver, Maxim and Stubendorff, Beatrice and Gille, Benjamin and Muckova, Petra and Wendler, Sindy and Prell, Tino and Ringer, Thomas M and Rhode, Heidrun and Stevens, Olivier and Claeys, Kristl G and Couwelier, Goedele and DʼHondt, Ann and Lamaire, Nikita and Tilkin, Petra and Van Reijen, Dimphna and Gourmaud, Sarah and Fedtke, Nadin and Heiling, Bianka and Rumpel, Matthias and Rödiger, Annekathrin and Gunkel, Anne and Witte, Otto W and Paquet, Claire and Vandenberghe, Rik and Grosskreutz, Julian and Van Damme, Philip
Neurology, ISSN 0028-3878, 06/2017, Volume 88, Issue 24, pp. 2302 - 2309
OBJECTIVE:To determine the diagnostic performance and prognostic value of phosphorylated neurofilament heavy chain (pNfH) and neurofilament light chain (NfL)... 
DIAGNOSIS | HEAVY-CHAIN | PROGNOSTIC BIOMARKER | CSF | AMYOTROPHIC-LATERAL-SCLEROSIS | PROGRESSION | CLINICAL NEUROLOGY | Severity of Illness Index | Single-Blind Method | Diagnosis, Differential | Phosphorylation | Prognosis | Cross-Sectional Studies | Amyotrophic Lateral Sclerosis - genetics | Humans | Middle Aged | Male | Disease Progression | Neurofilament Proteins - cerebrospinal fluid | Young Adult | Amyotrophic Lateral Sclerosis - cerebrospinal fluid | Adolescent | Aged, 80 and over | Adult | Female | Aged | Biomarkers - cerebrospinal fluid | Child | Longitudinal Studies
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
2. Full Text Safety and efficacy of eculizumab in anti-acetylcholine receptor antibody-positive refractory generalised myasthenia gravis (REGAIN): a phase 3, randomised, double-blind, placebo-controlled, multicentre study
by Howard, James F and Utsugisawa, Kimiaki and Benatar, Michael and Murai, Hiroyuki and Barohn, Richard J and Illa, Isabel and Jacob, Saiju and Vissing, John and Burns, Ted M and Kissel, John T and Muppidi, Srikanth and Nowak, Richard J and O'Brien, Fanny and Wang, Jing-Jing and Mantegazza, Renato and Mazia, Claudio Gabriel and Wilken, Miguel and Ortea, Carolina and Saba, Juliet and Rugiero, Marcelo and Bettini, Mariela and Vidal, Gonzalo and Vidal, Nuria and Garcia, Rebekah and Garcia, Sonia and Garcia, Alejandra Dalila and Lamont, Phillipa and Leong, Wai-Kuen and Boterhoven, Heidi and Fyfe, Beverly and Roberts, Leslie and Jasinarachchi, Mahi and Willlems, Natasha and Wanschitz, Julia and Löscher, Wolfgang and De Bleecker, Jan and Van den Abeele, Guy and de Koning, Kathy and De Mey, Katrien and Mercelis, Rudy and Wagemaekers, Linda and Mahieu, Delphine and Van Damme, Philip and Smetcoren, Charlotte and Stevens, Olivier and Verjans, Sarah and D'Hondt, Ann and Tilkin, Petra and Alves de Siqueira Carvalho, Alzira and Hasan, Rosa and Dias Brockhausen, Igor and Feder, David and Ambrosio, Daniel and Melo, Ana Paula and Rocha, Rosana and Rosa, Bruno and Veiga, Thabata and Augusto da Silva, Luiz and Gonçalves Geraldo, Jordana and da Penha Morita Ananias, Maria and Nogueira Coelho, Erica and Paiva, Gabriel and Pozo, Marina and Prando, Natalia and Dada Martineli Torres, Debora and Fernanda Butinhao, Cristiani and Coelho, Erica and Renata Cubas Volpe, Luciana and Duran, Gustavo and Gomes da Silva, Tamires Cristina and Otavio Maia Gonçalves, Luiz and Pazetto, Lucas Eduardo and Souza Duca, Luciana and Suriane Fialho, Tomás Augusto and Gheller Friedrich, Maurício André and Guerreiro, Alexandre and Mohr, Henrique and Pereira Martins, Maurer and da Cruz Pacheco, Daiane and Macagnan, Ana Paula and de Cassia Santos, Aline and Bulle Oliveira, Acary Souza and Amaral de Andrade, Ana Carolina and Annes, Marcelo and Cavalcante Lino, Valeria and Pinto, Wladimir and Miranda, Carolina and Carrara, Fernanda and Souza, Iandra and Genge, Angela and Massie, Rami and Campbell, Natasha and Bril, Vera and Katzberg, Hans and Soltani, Mehran and Ng, Eduardo and Siddiqi, Zaeem and Phan, Celile and Blackmore, Derrick and Vohanka, Stanislav and ... and REGAIN Study Grp and REGAIN Study Group
The Lancet Neurology, ISSN 1474-4422, 12/2017, Volume 16, Issue 12, pp. 976 - 986
Complement is likely to have a role in refractory generalised myasthenia gravis, but no approved therapies specifically target this system. Results from a... 
TRIAL | ENDPLATE | C3 | LOCALIZATION | COMPLEMENT INHIBITOR ECULIZUMAB | C9 | DAILY LIVING PROFILE | PAROXYSMAL-NOCTURNAL HEMOGLOBINURIA | ACETYLCHOLINE-RECEPTOR | END-PLATE | CLINICAL NEUROLOGY | Severity of Illness Index | Antibodies, Monoclonal, Humanized - adverse effects | Double-Blind Method | Myasthenia Gravis - blood | Outcome Assessment (Health Care) | Autoantibodies - blood | Humans | Middle Aged | Male | Antibodies, Monoclonal, Humanized - administration & dosage | Myasthenia Gravis - physiopathology | Antibodies, Monoclonal, Humanized - pharmacology | Adult | Female | Receptors, Cholinergic - immunology | Aged | Myasthenia Gravis - drug therapy | Drug Resistance | Studies | Neurology | Immunoglobulins | Activities of daily living | Myasthenia gravis | Transplants & implants | Neuromuscular junctions | Myasthenia | Patients
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
3. Full Text Minocycline delays disease onset and mortality in a transgenic model of ALS
by Van Den Bosch, Ludo and Tilkin, Petra and Lemmens, Griet and Robberecht, Wim
Neuroreport, ISSN 0959-4965, 06/2002, Volume 13, Issue 8, pp. 1067 - 1070
Microglial activation is thought to contribute to the progression of selective motor neuron death during amyotrophic lateral sclerosis (ALS). As minocycline... 
Amyotrophic lateral sclerosis | Inflammation | Neurodegeneration | Microglia | MOTOR-NEURONS | ACTIVATION | neurodegeneration | SPINAL-CORD | ISCHEMIA | AMYOTROPHIC-LATERAL-SCLEROSIS | amyotrophic lateral sclerosis | NEUROSCIENCES | FAMILIAL ALS | TETRACYCLINES | inflammation | MOUSE MODEL | ANIMAL-MODEL | microglia | PROGRESSION | Neuroprotective Agents - therapeutic use | Microglia - metabolism | Motor Activity - physiology | Spinal Cord - drug effects | Age Factors | Minocycline - pharmacology | Motor Activity - drug effects | Male | Amyotrophic Lateral Sclerosis - drug therapy | Motor Neurons - pathology | Dose-Response Relationship, Drug | Anti-Bacterial Agents - therapeutic use | Microglia - immunology | Neuroprotective Agents - pharmacology | Inflammation - drug therapy | Minocycline - therapeutic use | Spinal Cord - pathology | Female | Inflammation - mortality | Cell Survival - physiology | Motor Neurons - drug effects | Disease Models, Animal | Amyotrophic Lateral Sclerosis - immunology | Cell Survival - drug effects | Microglia - drug effects | Motor Neurons - immunology | Mice, Transgenic | Survival Rate | Treatment Outcome | Inflammation - immunology | Disease Progression | Amyotrophic Lateral Sclerosis - mortality | Spinal Cord - immunology | Animals | Anti-Bacterial Agents - pharmacology | Mice
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
4. Full Text Eculizumab improves fatigue in refractory generalized myasthenia gravis
by Andersen, Henning and Mantegazza, Renato and Wang, Jing Jing and O’Brien, Fanny and Patra, Kaushik and Howard Jr, James F and REGAIN Study Grp and REGAIN Study Group and The REGAIN Study Group
Quality of Life Research, ISSN 0962-9343, 8/2019, Volume 28, Issue 8, pp. 2247 - 2254
To evaluate the effect of eculizumab on perceived fatigue in patients with anti-acetylcholine receptor antibody-positive, refractory, generalized myasthenia... 
Public Health | Terminal complement inhibition | Myasthenia gravis | Medicine & Public Health | Quality of Life Research | Eculizumab | Fatigue | Complement | Sociology, general | Neuro-QOL Fatigue | Quality of life | PUBLIC, ENVIRONMENTAL & OCCUPATIONAL HEALTH | HEALTH CARE SCIENCES & SERVICES | HEALTH POLICY & SERVICES | QUALITY-OF-LIFE | Analysis | Brief Communication
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
5. Full Text Prognostic value of clinical and electrodiagnostic parameters at time of diagnosis in patients with amyotrophic lateral sclerosis
by Reniers, Wendeline and Schrooten, Maarten and Claeys, Kristl G and Tilkin, Petra and D'Hondt, Ann and Van Reijen, Dimphna and Couwelier, Goedele and Lamaire, Nikita and Robberecht, Wim and Fieuws, Steffen and Van Damme, Philip
Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, ISSN 2167-8421, 07/2017, Volume 18, Issue 5-6, pp. 341 - 350
Objective: To assess the added prognostic value of the aggregated clinical and electrodiagnostic data, which define a given diagnostic category according to... 
Prognosis, electromyography, electrodiagnostic testing, Awaji, revised El Escorial | SURVIVAL | CRITERIA | Awaji | EL-ESCORIAL | TESTS | Prognosis | POPULATION-BASED REGISTRY | ALGORITHM | ALS | SENSITIVITY | MOTOR-NEURON DISEASE | revised El Escorial | CLINICAL NEUROLOGY | electrodiagnostic testing | electromyography | Survival Rate - trends | Amyotrophic Lateral Sclerosis - physiopathology | Humans | Middle Aged | Amyotrophic Lateral Sclerosis - diagnosis | Male | Amyotrophic Lateral Sclerosis - mortality | Electromyography - trends | Electrodiagnosis - standards | Time Factors | Electrodiagnosis - trends | Delayed Diagnosis - trends | Female | Aged | Electromyography - standards
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
6. Full Text Long‐term safety and efficacy of eculizumab in generalized myasthenia gravis
by Muppidi, Srikanth and Utsugisawa, Kimiaki and Benatar, Michael and Murai, Hiroyuki and Barohn, Richard J and Illa, Isabel and Jacob, Saiju and Vissing, John and Burns, Ted M and Kissel, John T and Nowak, Richard J and Andersen, Henning and Casasnovas, Carlos and Bleecker, Jan L and Vu, Tuan H and Mantegazza, Renato and O'Brien, Fanny L and Wang, Jing Jing and Fujita, Kenji P and Howard, James F and Mazia, Claudio Gabriel and Wilken, Miguel and Barroso, Fabio and Saba, Juliet and Rugiero, Marcelo and Bettini, Mariela and Chaves, Marcelo and Vidal, Gonzalo and Garcia, Alejandra Dalila and Van den Abeele, Guy and de Koning, Kathy and De Mey, Katrien and Mercelis, Rudy and Mahieu, Délphine and Wagemaekers, Linda and Van Damme, Philip and Depreitere, Annelies and Schotte, Caroline and Smetcoren, Charlotte and Stevens, Olivier and Van Daele, Sien and Vandenbussche, Nicolas and Vanhee, Annelies and Verjans, Sarah and Vynckier, Jan and D'Hondt, Ann and Tilkin, Petra and Alves de Siqueira Carvalho, Alzira and Dias Brockhausen, Igor and Feder, David and Ambrosio, Daniel and César, Pamela and Melo, Ana Paula and Martins Ribeiro, Renata and Rocha, Rosana and Bezerra Rosa, Bruno and Veiga, Thabata and da Silva, Luiz Augusto and Santos Engel, Murilo and Gonçalves Geraldo, Jordana and Ananias Morita, Maria da Penha and Nogueira Coelho, Erica and Paiva, Gabriel and Pozo, Marina and Prando, Natalia and Martineli Torres, Debora Dada and Butinhao, Cristiani Fernanda and Duran, Gustavo and Gomes da Silva, Tamires Cristina and Otavio Maia Gonçalves, Luiz and Pazetto, Lucas Eduardo and Fialho, Tomás Augusto Suriane and Renata Cubas Volpe, Luciana and Souza Duca, Luciana and Gheller Friedrich, Maurício André and Guerreiro, Alexandre and Mohr, Henrique and Pereira Martins, Maurer and da Cruz Pacheco, Daiane and Ferreira, Luciana and Macagnan, Ana Paula and Pinto, Graziela and Santos, Aline and Souza Bulle Oliveira, Acary and Amaral Andrade, Ana Carolina and Annes, Marcelo and Duarte Silva, Liene and Cavalcante Lino, Valeria and Pinto, Wladimir and Assis, Natália and Carrara, Fernanda and Miranda, Carolina and Souza, Iandra and Fernandes, Patricia and Siddiqi, Zaeem and Phan, Cecile and Narayan, Jeffrey and Blackmore, Derrick and Mallon, Ashley and Roderus, Rikki and ... and REGAIN Study Grp and Regain Study Group and for the Regain Study Group
Muscle & Nerve, ISSN 0148-639X, 07/2019, Volume 60, Issue 1, pp. 14 - 24
Introduction : Eculizumab is effective and well tolerated in patients with antiacetylcholine receptor antibody‐positive refractory generalized myasthenia... 
MGC | myasthenia gravis | MG‐ADL | eculizumab | QMG | MG‐QOL15 | MG-ADL | MG-QOL15 | COMPLEMENT INHIBITOR ECULIZUMAB | ANTIBODY | NEUROSCIENCES | ACETYLCHOLINE-RECEPTOR | CLINICAL NEUROLOGY | THERAPY | DOUBLE-BLIND | Effectiveness | Activities of daily living | Antibodies | Muscles | Pharmacology | Quality of life | Refractory materials | Myasthenia gravis | Neuromuscular junctions | Remission | Myasthenia | Safety | Muscular strength | Clinical | Clinical s
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
7. Full Text Correction to: Eculizumab improves fatigue in refractory generalized myasthenia gravis
by Andersen, Henning and Mantegazza, Renato and Wang, Jing Jing and O’Brien, Fanny and Patra, Kaushik and Howard Jr, James F and REGAIN Study Group and The REGAIN Study Group
Quality of Life Research, ISSN 0962-9343, 8/2019, Volume 28, Issue 8, pp. 2255 - 2255
The article “Eculizumab improves fatigue in refractory generalized myasthenia gravis”, written by “Henning Andersen, Renato Mantegazza, Jing Jing Wang, Fanny... 
Quality of Life Research | Public Health | Medicine & Public Health | Sociology, general | Web portals | Medical colleges | Myasthenia gravis
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights